Parecoxib Sodium CAS 197502-82-2 99% Purity COX-2 Inhibitor API Intermediate for Anti-inflammatory fk
TDS
197502-82-2
Reagent Grade
99%
qingdao
//
10mg, 25mg, 50mg, 100mg, 1g
Yes
2026-10-25
Medetomidine,Medetomidine hydrochloride,D-Lysergic Acid Methyl Ester,SR17018,Fluralaner,GS-441524
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceParecoxib sodium is an injectable COX-2 inhibitor, launched as an anti-inflammatory agent and for the management of acute pain. Parecoxib is an amide prodrug of Pharmacia’s valdecoxib. It can be administered by either i.m. or i.v. routes, in contrast to other currently available COX-2 inhibitors which are poorly watersoluble. Parecoxib sodium can be prepared from valdecoxib by acylation of the sulfonamide with propionic anhydride. Parecoxib sodium exhibited potent acute and chronic antiinflammatory activity in rats, as demonstrated in the carrageenan air pouch model, where 98% of inhibition was achieved with the dose of 0.3mg/kg, and in the adjuvant arthritis model (ED50= 0.08mglkg). Moreover, in the carrageenan footpad edema model, parecoxib sodium showed excellent efficacy (ED50= Smglkg) and a rapid onset of action comparable with the most potent analgesic ketorolac. In this model, it produced a complete blockade of the carrageenan-induced hyperalgesia within 1 h after iv. administration. Pharmacokinetic studies indicated that parecoxib sodium completely and rapidly converted in valdecoxib with bioequivalence found between parenterally administered parecoxib sodium and orally administered valdecoxib. The maximum plasma concentrations of valdecoxib were 2530% greater after iv. than i.m. administration of parecoxib and tnax was respectively 0.5 h after iv. and 1.5 h after i.m. administration. Parecoxib sodium had greater gastrointestinal tolerance than ketorolac and had no significant effect on platelet aggregation. Parecoxib sodium was as effective as ketorolac or even superior to morphine and placebo in the treatment of severe pain (such as that observed following gynaecologic or orthopaedic surgery). Mean times to rescue medication were longer with parecoxib compared to morphine. Parecoxib sodium works 12-14 min after i.v. administration and a dose of 40 mg provides good or excellent relief of pain in approximately 90% of patients. Thus, parecoxib sodium is a non-narcotic, specific COX-2 inhibitor, which provides potent analgesic ability and fulfils some important requirements for the pain management in the post-operative period such as i.v. formulation, rapidity of action, and short half-life. Furthermore, although valdecoxib is a substrate for CYP3A4 as other drugs used in the perioperative period, it does not interfere either with the metabolism of the sedative/tranquilizer, midazolam, or with the intravenous anesthetic propofol.Research & Reference Note
Parecoxib Sodium CAS 197502-82-2 99% Purity COX-2 Inhibitor API Intermediate for Anti-inflammatory fk is listed on ECHEMI for industrial / laboratory sourcing. This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Authoritative sourcesDisclaimer: This listing is for industrial and laboratory research use. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Reviewed by ECHEMI Scientific Review - Platform editorial review for research chemicals
Certificates-
TDS
Basic Info-
Product Name:
PARECOXIB NA
Other Name:PARECOXIB NA
CAS No.:197502-82-2
Molecular Formula:C19H17N2NaO4S
InChIKeys:InChIKey=IMBMHWVEMVJSIQ-UHFFFAOYSA-N
Molecular Weight:392.4
Categories:
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Medetomidine,Medetomidine hydrochloride,D-Lysergic Acid Methyl Ester,SR17018,Fluralaner,GS-441524
-
Location:
RONGSHENG BEIYUANDAJIE 9, LICHENG DISTRICT,JINAN, SHANDONG CHINA
-
Payment Terms:
TT against copy of documents,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7 days
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2022
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
More from this Seller
-
-
-
Verbascose 98% Purity Natural Oligosaccharide Reference Standard CAS 546-62-3 HPLC Grade Small Molecule Compound
Research Grade / 98%
$57-62/G FOB
-
-
-
-
Fezolinetant CAS 1629229-37-3 99% Purity Neurokinin-3 Receptor Antagonist API Intermediate fk
Reagent Grade / 99%
$100-130/G FOB
-
-
-
-
Vonoprazan Fumarate CAS 881681-01-2 99% Purity Potassium-Competitive Acid Blocker API Intermediate fk
Reagent Grade / 99%
$100-130/G FOB
-
-
-
-
sr 15099 cas 2134602-44-9 SR-17018 Impurity 4 kr lab research use sr15099 kr
Reagent Grade / 99%
$1/G FOB
-